Stocks · News reference
As announced, Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two commercialized
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced the initiation of the commercial launch of Neonorm Dog, a new extension of Jaguar's Neonorm franchise for companion and production animals.
Read original at benzingaJaguar Health (NASDAQ:JAGX) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and
Read original at benzingaFiled: 2026-08-19 AccNo: 0001193125-26-356915 Size: 213 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarJaguar Health (NASDAQ:JAGX) reported quarterly losses of $(15.70) per share. This is a 95.63 percent increase over losses of $(358.94) per share from the same period last year. The company reported $1.225 million in
Read original at benzinga